The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists
Identifieur interne : 001190 ( Main/Corpus ); précédent : 001189; suivant : 001191The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists
Auteurs : Vibeke Guldbrand Rasmussen ; Karen Stergaard ; Erik Dupont ; Steen Hvitfeldt PoulsenSource :
- Movement Disorders [ 0885-3185 ] ; 2011-04.
English descriptors
- KwdEn :
Abstract
Objectives:: Several observational studies suggest an association between treatment with ergoline‐derived dopamine agonists and valvular regurgitation. In this article, we present an overview of the literature and conduct a meta‐analysis. Methods:: Observational studies addressing the frequency of moderate or severe valvular regurgitation among ergoline‐treated patients with Parkinson's disease were considered for a meta‐analysis. Pooled risk estimates and the risk of increased pulmonary artery pressure were calculated. Results:: The pooling of data from well‐designed observational studies documented that both pergolide (RR = 3.05 [1.71–5.44]) and cabergoline (RR = 6.38 [3.17–12.81]) represent a substantially increased risk of developing moderate to severe valvular regurgitation. In addition, pergolide, but not cabergoline, was associated with an increase in pulmonary artery pressure. Conclusions:: The present meta‐analysis confirmed a statistically significant association between pergolide and cabergoline treatment and the risk of moderate to severe valvular regurgitation. An association between bromocriptine and valvular regurgitation cannot be entirely ruled out. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23470
Links to Exploration step
ISTEX:A3521F2ADEA85DDD6FC91814A070765A51D749C2Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists</title><author><name sortKey="Rasmussen, Vibeke Guldbrand" sort="Rasmussen, Vibeke Guldbrand" uniqKey="Rasmussen V" first="Vibeke Guldbrand" last="Rasmussen">Vibeke Guldbrand Rasmussen</name><affiliation><mods:affiliation>Department of Cardiology, Aarhus University Hospital, Skejby, Denmark</mods:affiliation></affiliation></author><author><name sortKey=" Stergaard, Karen" sort=" Stergaard, Karen" uniqKey=" Stergaard K" first="Karen" last=" Stergaard">Karen Stergaard</name><affiliation><mods:affiliation>Department of Neurology, Aarhus University Hospital, Denmark</mods:affiliation></affiliation></author><author><name sortKey="Dupont, Erik" sort="Dupont, Erik" uniqKey="Dupont E" first="Erik" last="Dupont">Erik Dupont</name><affiliation><mods:affiliation>Department of Neurology, Aarhus University Hospital, Denmark</mods:affiliation></affiliation></author><author><name sortKey="Poulsen, Steen Hvitfeldt" sort="Poulsen, Steen Hvitfeldt" uniqKey="Poulsen S" first="Steen Hvitfeldt" last="Poulsen">Steen Hvitfeldt Poulsen</name><affiliation><mods:affiliation>Department of Cardiology, Aarhus University Hospital, Skejby, Denmark</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A3521F2ADEA85DDD6FC91814A070765A51D749C2</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/mds.23470</idno><idno type="url">https://api.istex.fr/document/A3521F2ADEA85DDD6FC91814A070765A51D749C2/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001190</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists</title><author><name sortKey="Rasmussen, Vibeke Guldbrand" sort="Rasmussen, Vibeke Guldbrand" uniqKey="Rasmussen V" first="Vibeke Guldbrand" last="Rasmussen">Vibeke Guldbrand Rasmussen</name><affiliation><mods:affiliation>Department of Cardiology, Aarhus University Hospital, Skejby, Denmark</mods:affiliation></affiliation></author><author><name sortKey=" Stergaard, Karen" sort=" Stergaard, Karen" uniqKey=" Stergaard K" first="Karen" last=" Stergaard">Karen Stergaard</name><affiliation><mods:affiliation>Department of Neurology, Aarhus University Hospital, Denmark</mods:affiliation></affiliation></author><author><name sortKey="Dupont, Erik" sort="Dupont, Erik" uniqKey="Dupont E" first="Erik" last="Dupont">Erik Dupont</name><affiliation><mods:affiliation>Department of Neurology, Aarhus University Hospital, Denmark</mods:affiliation></affiliation></author><author><name sortKey="Poulsen, Steen Hvitfeldt" sort="Poulsen, Steen Hvitfeldt" uniqKey="Poulsen S" first="Steen Hvitfeldt" last="Poulsen">Steen Hvitfeldt Poulsen</name><affiliation><mods:affiliation>Department of Cardiology, Aarhus University Hospital, Skejby, Denmark</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-04">2011-04</date><biblScope unit="volume">26</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="801">801</biblScope><biblScope unit="page" to="806">806</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">A3521F2ADEA85DDD6FC91814A070765A51D749C2</idno><idno type="DOI">10.1002/mds.23470</idno><idno type="ArticleID">MDS23470</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson</term><term>dopamine agonist</term><term>ergolines</term><term>fibrosis</term><term>heart valve</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objectives:: Several observational studies suggest an association between treatment with ergoline‐derived dopamine agonists and valvular regurgitation. In this article, we present an overview of the literature and conduct a meta‐analysis. Methods:: Observational studies addressing the frequency of moderate or severe valvular regurgitation among ergoline‐treated patients with Parkinson's disease were considered for a meta‐analysis. Pooled risk estimates and the risk of increased pulmonary artery pressure were calculated. Results:: The pooling of data from well‐designed observational studies documented that both pergolide (RR = 3.05 [1.71–5.44]) and cabergoline (RR = 6.38 [3.17–12.81]) represent a substantially increased risk of developing moderate to severe valvular regurgitation. In addition, pergolide, but not cabergoline, was associated with an increase in pulmonary artery pressure. Conclusions:: The present meta‐analysis confirmed a statistically significant association between pergolide and cabergoline treatment and the risk of moderate to severe valvular regurgitation. An association between bromocriptine and valvular regurgitation cannot be entirely ruled out. © 2011 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Vibeke Guldbrand Rasmussen PhD</name><affiliations><json:string>Department of Cardiology, Aarhus University Hospital, Skejby, Denmark</json:string></affiliations></json:item><json:item><name>Karen Østergaard DMSci</name><affiliations><json:string>Department of Neurology, Aarhus University Hospital, Denmark</json:string></affiliations></json:item><json:item><name>Erik Dupont MD</name><affiliations><json:string>Department of Neurology, Aarhus University Hospital, Denmark</json:string></affiliations></json:item><json:item><name>Steen Hvitfeldt Poulsen DMSci</name><affiliations><json:string>Department of Cardiology, Aarhus University Hospital, Skejby, Denmark</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dopamine agonist</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>fibrosis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>ergolines</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>heart valve</value></json:item></subject><articleId><json:string>MDS23470</json:string></articleId><language><json:string>eng</json:string></language><abstract>Objectives:: Several observational studies suggest an association between treatment with ergoline‐derived dopamine agonists and valvular regurgitation. In this article, we present an overview of the literature and conduct a meta‐analysis. Methods:: Observational studies addressing the frequency of moderate or severe valvular regurgitation among ergoline‐treated patients with Parkinson's disease were considered for a meta‐analysis. Pooled risk estimates and the risk of increased pulmonary artery pressure were calculated. Results:: The pooling of data from well‐designed observational studies documented that both pergolide (RR = 3.05 [1.71–5.44]) and cabergoline (RR = 6.38 [3.17–12.81]) represent a substantially increased risk of developing moderate to severe valvular regurgitation. In addition, pergolide, but not cabergoline, was associated with an increase in pulmonary artery pressure. Conclusions:: The present meta‐analysis confirmed a statistically significant association between pergolide and cabergoline treatment and the risk of moderate to severe valvular regurgitation. An association between bromocriptine and valvular regurgitation cannot be entirely ruled out. © 2011 Movement Disorder Society</abstract><qualityIndicators><score>5.497</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>1217</abstractCharCount><pdfWordCount>3625</pdfWordCount><pdfCharCount>25259</pdfCharCount><pdfPageCount>6</pdfPageCount><abstractWordCount>156</abstractWordCount></qualityIndicators><title>The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists</title><genre><json:string>book reviews</json:string></genre><host><volume>26</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>6</total><last>806</last><first>801</first></pages><issn><json:string>0885-3185</json:string></issn><issue>5</issue><subject><json:item><value>Review</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.1002/mds.23470</json:string></doi><id>A3521F2ADEA85DDD6FC91814A070765A51D749C2</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/A3521F2ADEA85DDD6FC91814A070765A51D749C2/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/A3521F2ADEA85DDD6FC91814A070765A51D749C2/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/A3521F2ADEA85DDD6FC91814A070765A51D749C2/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2011</date></publicationStmt><notesStmt><note>Author Roles and Disclosures</note><note type="content">*Relevant conflict of interest/financial disclosures: As research fellow Dr. Rasmussen received financial support from the Danish Heart Foundation and The Danish Parkinson's Disease Association. Dr. Østergaard received research grants from the Danish Medical Research Council, the Lundbeck Foundation, and the Danish Parkinson's disease. Drs. Dupont and Poulsen have no relevant disclosures. Full financial disclosures and author roles can be found in the online version of this article.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists</title><author><persName><forename type="first">Vibeke Guldbrand</forename><surname>Rasmussen</surname></persName><roleName type="degree">PhD</roleName><note type="correspondence"><p>Correspondence: Ph.D.; Department of Cardiology, Aarhus University Hospital, Skejby, Brendstrupgaardsvej, 8200 Aarhus N, Denmark</p></note><affiliation>Department of Cardiology, Aarhus University Hospital, Skejby, Denmark</affiliation></author><author><persName><forename type="first">Karen</forename><surname>Østergaard</surname></persName><roleName type="degree">DMSci</roleName><note type="biography">The study risk estimate is calculated by adding 1 to all four cells in the 2×2 table.</note><affiliation>The study risk estimate is calculated by adding 1 to all four cells in the 2×2 table.</affiliation><affiliation>Department of Neurology, Aarhus University Hospital, Denmark</affiliation></author><author><persName><forename type="first">Erik</forename><surname>Dupont</surname></persName><roleName type="degree">MD</roleName><note type="biography">Note: The study risk estimate is calculated by adding 1 to all four cells in the 2×2 table.</note><note type="biography">Relevant conflict of interest/financial disclosures: As research fellow Dr. Rasmussen received financial support from the Danish Heart Foundation and The Danish Parkinson's Disease Association. Dr. Østergaard received research grants from the Danish Medical Research Council, the Lundbeck Foundation, and the Danish Parkinson's disease. Drs. Dupont and Poulsen have no relevant disclosures. Full financial disclosures and author roles can be found in the online version of this article.</note><affiliation>Note: The study risk estimate is calculated by adding 1 to all four cells in the 2×2 table.</affiliation><affiliation>Relevant conflict of interest/financial disclosures: As research fellow Dr. Rasmussen received financial support from the Danish Heart Foundation and The Danish Parkinson's Disease Association. Dr. Østergaard received research grants from the Danish Medical Research Council, the Lundbeck Foundation, and the Danish Parkinson's disease. Drs. Dupont and Poulsen have no relevant disclosures. Full financial disclosures and author roles can be found in the online version of this article.</affiliation><affiliation>Department of Neurology, Aarhus University Hospital, Denmark</affiliation></author><author><persName><forename type="first">Steen Hvitfeldt</forename><surname>Poulsen</surname></persName><roleName type="degree">DMSci</roleName><affiliation>Department of Cardiology, Aarhus University Hospital, Skejby, Denmark</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-04"></date><biblScope unit="volume">26</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="801">801</biblScope><biblScope unit="page" to="806">806</biblScope></imprint></monogr><idno type="istex">A3521F2ADEA85DDD6FC91814A070765A51D749C2</idno><idno type="DOI">10.1002/mds.23470</idno><idno type="ArticleID">MDS23470</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2011</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Objectives:: Several observational studies suggest an association between treatment with ergoline‐derived dopamine agonists and valvular regurgitation. In this article, we present an overview of the literature and conduct a meta‐analysis. Methods:: Observational studies addressing the frequency of moderate or severe valvular regurgitation among ergoline‐treated patients with Parkinson's disease were considered for a meta‐analysis. Pooled risk estimates and the risk of increased pulmonary artery pressure were calculated. Results:: The pooling of data from well‐designed observational studies documented that both pergolide (RR = 3.05 [1.71–5.44]) and cabergoline (RR = 6.38 [3.17–12.81]) represent a substantially increased risk of developing moderate to severe valvular regurgitation. In addition, pergolide, but not cabergoline, was associated with an increase in pulmonary artery pressure. Conclusions:: The present meta‐analysis confirmed a statistically significant association between pergolide and cabergoline treatment and the risk of moderate to severe valvular regurgitation. An association between bromocriptine and valvular regurgitation cannot be entirely ruled out. © 2011 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson</term></item><item><term>dopamine agonist</term></item><item><term>fibrosis</term></item><item><term>ergolines</term></item><item><term>heart valve</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Review</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2010-04-12">Received</change><change when="2010-09-13">Registration</change><change when="2011-04">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/A3521F2ADEA85DDD6FC91814A070765A51D749C2/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="50"><doi origin="wiley" registered="yes">10.1002/mds.v26.5</doi><numberingGroup><numbering type="journalVolume" number="26">26</numbering><numbering type="journalIssue">5</numbering></numberingGroup><coverDate startDate="2011-04">April 2011</coverDate></publicationMeta><publicationMeta level="unit" type="bookReview" position="80" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.23470</doi><idGroup><id type="unit" value="MDS23470"></id></idGroup><countGroup><count type="pageTotal" number="6"></count></countGroup><titleGroup><title type="articleCategory">Review</title><title type="tocHeading1">Reviews</title></titleGroup><copyright ownership="thirdParty">Copyright © 2011 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2010-04-12"></event><event type="manuscriptRevised" date="2010-07-13"></event><event type="manuscriptAccepted" date="2010-09-13"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.5.2 mode:FullText" date="2011-07-19"></event><event type="publishedOnlineEarlyUnpaginated" date="2011-01-24"></event><event type="publishedOnlineFinalForm" date="2011-04-21"></event><event type="firstOnline" date="2011-01-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">801</numbering><numbering type="pageLast">806</numbering></numberingGroup><correspondenceTo>Ph.D.; Department of Cardiology, Aarhus University Hospital, Skejby, Brendstrupgaardsvej, 8200 Aarhus N, Denmark</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS23470.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="3"></count><count type="referenceTotal" number="40"></count><count type="wordTotal" number="5454"></count></countGroup><titleGroup><title type="main" xml:lang="en">The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists<link href="#fn2"></link></title><title type="short" xml:lang="en">Ergolines and Valvular Regurgitation</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Vibeke Guldbrand</givenNames><familyName>Rasmussen</familyName><degrees>PhD</degrees></personName><contactDetails><email>vibeke.guldbrand@ki.au.dk</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2" noteRef="#fn1"><personName><givenNames>Karen</givenNames><familyName>Østergaard</familyName><degrees>DMSci</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af2" noteRef="#fn1 #fn2"><personName><givenNames>Erik</givenNames><familyName>Dupont</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Steen Hvitfeldt</givenNames><familyName>Poulsen</familyName><degrees>DMSci</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="DK" type="organization"><unparsedAffiliation>Department of Cardiology, Aarhus University Hospital, Skejby, Denmark</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="DK" type="organization"><unparsedAffiliation>Department of Neurology, Aarhus University Hospital, Denmark</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson</keyword><keyword xml:id="kwd2">dopamine agonist</keyword><keyword xml:id="kwd3">fibrosis</keyword><keyword xml:id="kwd4">ergolines</keyword><keyword xml:id="kwd5">heart valve</keyword></keywordGroup><supportingInformation><supportingInfoItem><mediaResource alt="supporting information" href="urn-x:wiley:08853185:media:mds23470:MDS_23470_sm_authorroles"></mediaResource><caption>Author Roles and Disclosures</caption></supportingInfoItem></supportingInformation><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><section xml:id="abs1-1"><title type="main">Objectives:</title><p>Several observational studies suggest an association between treatment with ergoline‐derived dopamine agonists and valvular regurgitation. In this article, we present an overview of the literature and conduct a meta‐analysis.</p></section><section xml:id="abs1-2"><title type="main">Methods:</title><p>Observational studies addressing the frequency of moderate or severe valvular regurgitation among ergoline‐treated patients with Parkinson's disease were considered for a meta‐analysis. Pooled risk estimates and the risk of increased pulmonary artery pressure were calculated.</p></section><section xml:id="abs1-3"><title type="main">Results:</title><p>The pooling of data from well‐designed observational studies documented that both pergolide (RR = 3.05 [1.71–5.44]) and cabergoline (RR = 6.38 [3.17–12.81]) represent a substantially increased risk of developing moderate to severe valvular regurgitation. In addition, pergolide, but not cabergoline, was associated with an increase in pulmonary artery pressure.</p></section><section xml:id="abs1-4"><title type="main">Conclusions:</title><p>The present meta‐analysis confirmed a statistically significant association between pergolide and cabergoline treatment and the risk of moderate to severe valvular regurgitation. An association between bromocriptine and valvular regurgitation cannot be entirely ruled out. © 2011 Movement Disorder Society</p></section></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn2"><p><b>Relevant conflict of interest/financial disclosures:</b> As research fellow Dr. Rasmussen received financial support from the Danish Heart Foundation and The Danish Parkinson's Disease Association. Dr. Østergaard received research grants from the Danish Medical Research Council, the Lundbeck Foundation, and the Danish Parkinson's disease. Drs. Dupont and Poulsen have no relevant disclosures. Full financial disclosures and author roles can be found in the online version of this article.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Ergolines and Valvular Regurgitation</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists</title></titleInfo><name type="personal"><namePart type="given">Vibeke Guldbrand</namePart><namePart type="family">Rasmussen</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Cardiology, Aarhus University Hospital, Skejby, Denmark</affiliation><description>Correspondence: Ph.D.; Department of Cardiology, Aarhus University Hospital, Skejby, Brendstrupgaardsvej, 8200 Aarhus N, Denmark</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Karen</namePart><namePart type="family">Østergaard</namePart><namePart type="termsOfAddress">DMSci</namePart><affiliation>Department of Neurology, Aarhus University Hospital, Denmark</affiliation><description>The study risk estimate is calculated by adding 1 to all four cells in the 2×2 table.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Erik</namePart><namePart type="family">Dupont</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Aarhus University Hospital, Denmark</affiliation><description>Note: The study risk estimate is calculated by adding 1 to all four cells in the 2×2 table.</description><description>Relevant conflict of interest/financial disclosures: As research fellow Dr. Rasmussen received financial support from the Danish Heart Foundation and The Danish Parkinson's Disease Association. Dr. Østergaard received research grants from the Danish Medical Research Council, the Lundbeck Foundation, and the Danish Parkinson's disease. Drs. Dupont and Poulsen have no relevant disclosures. Full financial disclosures and author roles can be found in the online version of this article.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Steen Hvitfeldt</namePart><namePart type="family">Poulsen</namePart><namePart type="termsOfAddress">DMSci</namePart><affiliation>Department of Cardiology, Aarhus University Hospital, Skejby, Denmark</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="book reviews" displayLabel="bookReview"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2011-04</dateIssued><dateCaptured encoding="w3cdtf">2010-04-12</dateCaptured><dateValid encoding="w3cdtf">2010-09-13</dateValid><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">3</extent><extent unit="references">40</extent><extent unit="words">5454</extent></physicalDescription><abstract lang="en">Objectives:: Several observational studies suggest an association between treatment with ergoline‐derived dopamine agonists and valvular regurgitation. In this article, we present an overview of the literature and conduct a meta‐analysis. Methods:: Observational studies addressing the frequency of moderate or severe valvular regurgitation among ergoline‐treated patients with Parkinson's disease were considered for a meta‐analysis. Pooled risk estimates and the risk of increased pulmonary artery pressure were calculated. Results:: The pooling of data from well‐designed observational studies documented that both pergolide (RR = 3.05 [1.71–5.44]) and cabergoline (RR = 6.38 [3.17–12.81]) represent a substantially increased risk of developing moderate to severe valvular regurgitation. In addition, pergolide, but not cabergoline, was associated with an increase in pulmonary artery pressure. Conclusions:: The present meta‐analysis confirmed a statistically significant association between pergolide and cabergoline treatment and the risk of moderate to severe valvular regurgitation. An association between bromocriptine and valvular regurgitation cannot be entirely ruled out. © 2011 Movement Disorder Society</abstract><note type="additional physical form">Author Roles and Disclosures</note><note type="content">*Relevant conflict of interest/financial disclosures: As research fellow Dr. Rasmussen received financial support from the Danish Heart Foundation and The Danish Parkinson's Disease Association. Dr. Østergaard received research grants from the Danish Medical Research Council, the Lundbeck Foundation, and the Danish Parkinson's disease. Drs. Dupont and Poulsen have no relevant disclosures. Full financial disclosures and author roles can be found in the online version of this article.</note><subject lang="en"><genre>Keywords</genre><topic>Parkinson</topic><topic>dopamine agonist</topic><topic>fibrosis</topic><topic>ergolines</topic><topic>heart valve</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Review</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>801</start><end>806</end><total>6</total></extent></part></relatedItem><identifier type="istex">A3521F2ADEA85DDD6FC91814A070765A51D749C2</identifier><identifier type="DOI">10.1002/mds.23470</identifier><identifier type="ArticleID">MDS23470</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2011 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001190 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001190 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:A3521F2ADEA85DDD6FC91814A070765A51D749C2
|texte= The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists
}}
| This area was generated with Dilib version V0.6.23. |  |